Taken together, our data reveal a critical role of AK in modulating vascular adenosine responses and suggest pharmacological inhibitors of AK in the treatment of conditions associated with hypoxia-induced vascular leakage (e.g. sepsis or acute lung injury).
Introduction
Previous studies have shown that extracellular adenosine levels are increased during limited oxygen availability and play a critical role in vascular adaptation to hypoxia. [1] [2] [3] Extracellular adenosine mainly stems from phosphohydrolysis of nucleotide precursor molecules (ATP, ADP or AMP) via the ecto-apyrase (CD39, conversion of ATP/ADP to AMP) and ecto-5'-nucleotidase (CD73, converison of AMP to adenosine), which are both highly expressed in vascular endothelia. 4 Once generated into the extracellular space, adenosine can signal through either of four G-protein coupled adenosine-receptors (A1AR, A2AAR, A2BAR, or A3AR). All of these receptors are expressed on vascular endothelia 4 and have been implicated in tissue-protection in different models of injury. 1, [5] [6] [7] [8] [9] Following receptor activation, vascular adenosine signaling is terminated by diffusion of adenosine away from the receptor and rapid transport from the extracellular towards the intracellular space mainly via equilibrative nucleoside transporters (ENTs). 10 Having reached the intracellular space, adenosine can either undergo deamination by adenosine deaminase to inosine 11 or conversion to AMP by adenosine kinase (AK, EC 2.7.1.20). 12 Interestingly, despite its intracellular location, AK has been shown to regulate extracellular adenosine signaling. [12] [13] [14] In fact, inhibition of AK efficiently elevates cytoplasmatic adenosine levels. For example, functional studies in the heart have shown that inhibition of AK can elevate extracellular adenosine levels 12 and contributes to adenosine dependent cardioprotection. 13 Moveover, a very elegant study of rat hypocampal adenosine metabolism found that during conditions which provide adequate oxygen and glucose supply, adenosine kinase plays a much greater role than adenosine deaminase (metabolism of adenosine to inosine) in regulating the extracellular concentration of adenosine.
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As an important endpoint of vascular adenosine signaling, several studies have investigated the role of extracellular adenosine in vascular barrier function. 4, 16, 17 In fact, changes in vascular barrier function closely coincide with tissue injuries of many etiologies, and result in fluid loss, edema, and organ dysfunction. 18 As such, endothelial permeability is highly regulated and may increase markedly upon exposure to inflammatory stimuli or adverse conditions such as ischemia or hypoxia and studies have shown a critical role of extracellular adenosine in attenuating hypoxia associated vascular leakage. 4, 11, 17, [19] [20] [21] [22] For example, gene-targeted mice with defects in extracellular generation of adenosine (cd39 -/-or cd73 -/-mice) show profound increases in vascular leakage and pulmonary edema when exposed to ambient hypoxia. 4, 19 Similarly, studies using inhibitors of extracellular adenosine deaminase (e.g. deoxycoformycin) or adenosine uptake inhibitors (e.g. dipyridamole) found attenuated vascular leakage during hypoxia. 11, 17 Along these lines, we pursued the hypothesis that inhibition of AK-dependent conversion of adenosine to AMP may increase vascular adenosine signalling, resulting in barrier protection from hypoxia-induced vascular leak.
Materials and Methods

Endothelial Cell Culture
Human microvascular endothelial cells (HMEC-1), human umbilical vein endothelial cells (HUVEC) or CaCo-2 intestinal epithelia were cultured as described previously.
20,23
Transcriptional analysis
The transcriptional profile of endothelial cells subjected to normobaric hypoxia (12 h) was compared in RNA derived from control or hypoxic endothelia using quantitative genechip -4- -TGC CCT AAT TGC TTC CTG AG-3', antisense 5'-TTG GCA TTT AAG TGG   CAC TAT C-3'; human Toll-like GTTTGCTCCAACCAACTGCT-3; human ß-actin: sense 5'-GGT GGC TTT TAG GAT GGC AAG-3', antisense 5'-ACT GGA ACG GTG AAG GTG ACA-3';ß-actin was used in identical reactions to control for starting template. Real-time PCR was also performed from RNA isolations of human saphenous vein after ex vivo exposure to hypoxia as described previously.
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Protein analysis
HMEC-1, CaCo-2 or murine tissues were analyzed by Western blot using a rabbit polyclonal anti-AK (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a rabbit monoclonal anti-β-actin antibody (Cell Signaling, MA, USA) as described previously. 17 Cardiac immunohistochemistry was performed as described previously.
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Evaluation of adenosine kinase activity HMEC-1 were grown to full confluency and exposed as indicated to normoxia or different hours of hypoxia. In order to develop a model for kinetics of endothelial activity, we first measured etheno (E)-adenosine (E-Ado) conversion to E-AMP in lysates of HMEC-1 monolayers with different E-Ado concentrations (0.1-20 µM), and found optimal resolution of E-Ado conversion to E-AMP with 5 µM E-Ado concentrations. These conditions were used throughout for further measurements. After washing in HBSS, HMEC-1 were lysed in cold H 2 O and E-Ado was added. E-AMP was detected via HPLC as described previously. 19 AK activity was expressed as percentage of conversion of E-Ado to E-AMP. In control experiments, the AK inhibitor 5´-iodotubericidin (ITU, 10 µM), was used to demonstrate specificity for AK.
Stable repression of AK or HIF-1α by siRNA
HMEC-1 or CaCo-2 cells stably expressing psiRNA against AK or HIF-1α (HMEC-AK, CaCo-HIF1α) were generated as previously described. 22 The hairpin primer with the sequence 
Lentiviral vector design, production and transduction in CaCo-2 cells
Expression of oxygen-stable HIF-1α in CaCo-2 (CaCo-ΔODD) was achieved as previously described. 22 This cell line was a kind gift from Dr. Colgan and Dr. Westerman.
Measurement of adenosine
Adenosine was measured in supernatants of endothelia or after endothelial lysis with cold H 2 O by HPLC as previously described.
17
Macromolecule paracellular permeability assay
Endothelial barrier function was assessed as described previously.
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Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using a Chromatin Immunoprecipitation (ChIP) Assay Kit Chromatin incubated with only beads or IgG-control was used as control for nonspecific binding of DNA. 25 As a positive control for a known HIF- 
Results
AK transcript, protein, and function are repressed by hypoxia
Recent studies suggest that hypoxia promotes a vascular phenotype which supports high capacity for rapid nucleotide phosphohydrolysis and enhanced adenosine signaling. 4, 20 Based on the notion that attenuation of AK-dependent intracellular metabolism of adenosine to AMP can effectively increase extracellular adenosine levels, we pursued transcriptional responses of AK during hypoxia. We gained initial insight from microarray analysis showing a 42±0.06% repression of AK mRNA expression in hypoxic endothelia (HMEC-1, pO 2 20 torr, 24 hours, Figure 1A , P < 0.005). To confirm theses studies, we exposed confluent HMEC-1 or HUVEC to normoxia (ambient room air) or hypoxia (2% oxygen). As shown in Figure We extended these mRNA findings to examine AK protein expression in cultured HMEC-1.
As shown in Figure 1E , western blot analysis of lysates derived from HMEC-1 subjected to hypoxia (pO 2 ChIP assay with the known HIF-1-dependent gene TLR2 was used. 28 Prompted by this finding, we next pursued HIF-1α loss and gain of function studies in AK repression by hypoxia. As first step, we used a previously described HMEC-1 cell line expressing oxygen-stable HIF-1α (HMEC-ΔODD, Figure 3C ). 22 
Role of AK in adenosine-dependent barrier function in vitro.
For functional studies of AK in endothelial adenosine responses, we first generated an HMEC-1 cell line stably expressing psiRNA directed against AK (HMEC-AK). In control studies, a non-specific psiRNA was used (HMEC-Scr). These cells are characterized in Figure 7A and 7B by RT-PCR and Western Blot analysis, confirming siRNA repression of AK. Next, we used these cell lines to study adenosine-dependent barrier responses using a previously described model of endothelial barrier function. 4, 17 In fact, adenosine-dependent increases in endothelial barrier function (decreased flux of 70-kD FITC-dextran) were significantly enhanced following genetic repression of AK ( Figure 7C) . Similarly, inhibition of AK with 20 µM ITU was associated with significantly increased adenosine responses ( Figure 7D , ANOVA P<0.01).
Taken together, these results suggest that adenosine-dependent barrier protection is enhanced during genetic repression or pharmacologic inhibition of AK.
Inhibition of AK during hypoxia attenuates vascular leak in vivo.
Prompted by these in vitro findings, we next pursued the role of AK in hypoxia-associated vascular leakage in vivo. 19 For this purpose, mice were administered ITU (1 mg/Kg i.v.) or vehicle (DMSO), a dose previously shown to effectively inhibit murine AK in vivo. 13 To measure vascular barrier function, mice received the albumin marker Evan´s blue dye intravenously and were subjected to normoxia or nomobaric hypoxia (8% O 2 , 92% N 2 ) for 4 hours. Comparison of vascular permeability in ITU or vehicle-treated mice subjected to normobaric hypoxia revealed significantly increased vascular leak in all animals, however to a smaller degree in ITUtreated animals ( Figure 8A , P<0.05). Such protective effect of ITU was observed in all organs except the brain, and was particularly evident in the lungs. Changes in overall vascular leakage (Evan´s blue extravasation) between ITU or vehicle treated mice were also evident in open abdominal images taken at necropsy (Fig. 8B ). In addition, we assessed pulmonary edema by determining lung water content (wet-dry ratio). As shown in Figure 8C , hypoxia associated increases in lung water were attenuated following AK inhibition with ITU. These in vivo results suggest that inhibition of AK contributes to the in vivo resuscitation of vascular leak syndrome associated with hypoxia.
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Discussion
In the present studies, we explored the contribution of AK to vascular adenosine signaling. As part of innate adaptation to hypoxia, we found transcriptional repression of AK by hypoxia. In addition, this response is mechanistically determined, at least in part, by HIF-1. Moreover, the present studies suggest inhibition of AK as a pharmacological strategy to increase endothelial adenosine signaling and attenuate hypoxia-associated vascular leak.
These findings are consistent with previous work showing that hypoxia inhibits intracellular metabolism of adenosine to AMP. Decking et al. showed, by measuring adenosine and AMP concentrations in the coronary sinus and coronary arteries of isolated guinea pig hearts, that hypoxia is associated with a functional inhibition of AK. 12 The authors propose that hypoxia-associated inhibition of AK leads to site-specific increases of intracellular adenosine levels. As adenosine flux during ischemia or hypoxia is predominantly directed from the extracellular to the intracellular space, 8, 24, 29, 30 four cellular strategies may contribute to increasing extracellular adenosine signaling during hypoxia. First, adenosine production from precursor nucleotides is increased during hypoxia (e.g. by HIF-1-dependent induction of CD73). 4, 20 Secondly, hypoxia is associated with transcriptional induction of the A2BAR, thereby enhancing vascular adenosine signaling effects. 4, 22 Moreover, vascular adenosine uptake is attenuated due to transcriptional repression by ENTs. 10, 17 Finally, the present study reveals HIF-1-dependent repression of AK as additional mechanism to increase vascular adenosine signaling. Interestingly, all four mechanisms are transcriptionally regulated by HIF-1. 17, 20, 22 In fact, this highlights the role of oxygen sensing signalling pathways in transcriptional coordination of vascular responses during inflammation 31 or hypoxia. 32 Similar to the present studies showing AK in vascular adaptation, a previous study found AK inhibition in cardioprotection. 13 In fact, this very elegant study used a rat model of myocardial infarction and found that infarct sizes were reduced from 58.0 to 37.5% of the area at risk following AK inhibition with ITU. Moreover, the protective effects of AK where abolished with inhibitors of extracellular adenosine signaling, suggesting that the reduction of infarct sizes with AK inhibition is mediated by extracellular adenosine signaling. 
